Texas Permanent School Fund Corp Has $6.51 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Texas Permanent School Fund Corp grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 10.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 60,955 shares of the specialty pharmaceutical company's stock after purchasing an additional 5,856 shares during the period. Texas Permanent School Fund Corp owned about 0.10% of Jazz Pharmaceuticals worth $6,506,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rise Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock valued at $26,000 after buying an additional 203 shares in the last quarter. Versant Capital Management Inc grew its stake in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after acquiring an additional 269 shares during the period. GAMMA Investing LLC increased its holdings in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after acquiring an additional 116 shares in the last quarter. Gladius Capital Management LP acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter worth about $33,000. Finally, Cape Investment Advisory Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 14,600.0% during the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock valued at $36,000 after purchasing an additional 292 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Needham & Company LLC reissued a "buy" rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday. Morgan Stanley dropped their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an "equal weight" rating on the stock in a report on Friday, July 12th. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They issued a "buy" rating and a $169.00 price objective on the stock. Robert W. Baird dropped their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating on the stock in a research note on Thursday, August 1st. Finally, Wells Fargo & Company cut their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a report on Thursday, August 1st. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $173.07.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded up $1.32 during trading hours on Thursday, hitting $106.45. The company had a trading volume of 599,890 shares, compared to its average volume of 688,538. The business has a fifty day moving average of $109.83 and a 200-day moving average of $111.75. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The firm has a market cap of $6.71 billion, a price-to-earnings ratio of 22.15, a PEG ratio of 1.34 and a beta of 0.57. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $137.38.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.